Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group

[1]  Markus Schweizer,et al.  Group Techniques For Program Planning A Guide To Nominal Group And Delphi Processes , 2016 .

[2]  M. Cazzola,et al.  Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. , 2015, Blood.

[3]  P. Frankel,et al.  Impact of pretransplant serum ferritin level on risk of invasive mold infection after allogeneic hematopoietic stem cell transplantation , 2015, European journal of haematology.

[4]  M. Mohty,et al.  How we manage JAK inhibition in allogeneic transplantation for myelofibrosis , 2015, European journal of haematology.

[5]  M. Perales,et al.  Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Jianfeng Zhou,et al.  Reduced-intensity and myeloablative conditioning allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis and systematic review. , 2014, International journal of clinical and experimental medicine.

[7]  N. Kröger,et al.  Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  E. Estey,et al.  Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Lipton,et al.  Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning , 2014, Bone Marrow Transplantation.

[10]  Ayalew Tefferi,et al.  CME Information , 2014, Stahl's Illustrated Violence.

[11]  V. Najfeld,et al.  MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. , 2014, Blood.

[12]  R. Parkkola,et al.  Iron overload in allogeneic hematopoietic cell transplantation outcome: a meta-analysis. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  B. Savani,et al.  Preparative regimen dosing for hematopoietic stem cell transplantation in patients with chronic kidney disease: analysis of the literature and recommendations. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  P. Guglielmelli,et al.  CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients , 2014, Leukemia.

[15]  N. Kröger,et al.  JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis , 2014, Leukemia.

[16]  N. Kröger,et al.  Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  Alan M. Miller,et al.  Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  B. Savani,et al.  Preparative regimen dosing for hematopoietic stem cell transplantation in patients with chronic hepatic impairment: analysis of the literature and recommendations. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  M. Cazzola,et al.  The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients , 2014, Leukemia.

[20]  G. Superti-Furga,et al.  Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.

[21]  J. D. Fitzpatrick,et al.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.

[22]  M. Cazzola,et al.  Mutations and prognosis in primary myelofibrosis , 2013, Leukemia.

[23]  T. DeFor,et al.  Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content. , 2013, Blood.

[24]  M. Minden,et al.  Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. , 2013, Blood.

[25]  M. Pasquini,et al.  EFFECTS OF SPLEEN STATUS ON EARLY OUTCOMES AFTER HEMATOPOIETIC CELL TRANSPLANTATION , 2012, Bone Marrow Transplantation.

[26]  A. Takaori-Kondo,et al.  Splenic irradiation as a component of a reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly. , 2012, The Tohoku journal of experimental medicine.

[27]  P. Westervelt,et al.  Peripheral-blood stem cells versus bone marrow from unrelated donors. , 2012, The New England journal of medicine.

[28]  J. Lipton,et al.  Incidence and risk factors for early hepatotoxicity and its impact on survival in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  A. Elmaagacli,et al.  Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis , 2012, Haematologica.

[30]  R. Mesa,et al.  Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. , 2012, Leukemia research.

[31]  P. Hari,et al.  Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. , 2012, Blood.

[32]  A. Mead,et al.  Guideline for the diagnosis and management of myelofibrosis , 2012, British journal of haematology.

[33]  N. Kröger,et al.  Risk models predicting survival after reduced‐intensity transplantation for myelofibrosis , 2012, British journal of haematology.

[34]  H. Deeg,et al.  The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. , 2012, Blood.

[35]  P. Johansson,et al.  The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries , 2012, Bone Marrow Transplantation.

[36]  J. Simpson,et al.  Allogeneic hematopoietic cell transplantation for chronic myelofibrosis in Australia and New Zealand: older recipients receiving myeloablative conditioning at increased mortality risk. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[37]  M. Cazzola,et al.  Leukemia Risk Models in Primary Myelofibrosis: An International Working Group Study, , 2011 .

[38]  M. Griesshammer,et al.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Bernard,et al.  Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM‐TC) , 2011, British journal of haematology.

[40]  F. Passamonti,et al.  DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  A. Green,et al.  MPN-associated myelofibrosis (MPN-MF). , 2011, Leukemia research.

[42]  N. Kröger,et al.  Donor Lymphocyte Infusions and Second Transplantation as Salvage Treatment for Relapsed Myelofibrosis After Reduced-Intensity allografting. , 2010 .

[43]  N. Russell,et al.  The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study , 2010, Bone Marrow Transplantation.

[44]  S. Verstovsek,et al.  Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[45]  M. Cazzola,et al.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). , 2010, Blood.

[46]  N. Kröger,et al.  Outcome of transplantation for myelofibrosis. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[47]  G. Barosi,et al.  Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type , 2010, Bone Marrow Transplantation.

[48]  H. Einsele,et al.  Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. , 2009, Blood.

[49]  B. Andersson,et al.  Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis. , 2009 .

[50]  Y. Hildebrandt,et al.  JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. , 2009, Blood.

[51]  M. Kurokawa,et al.  Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[52]  R. Mesa,et al.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.

[53]  R. Fanin,et al.  Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) , 2008, Haematologica.

[54]  Allen R. Chen,et al.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[55]  R. Hoffman,et al.  Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation , 2008, British journal of haematology.

[56]  J. Cheong,et al.  Transfusion-Associated Iron Overload as an Adverse Risk Factor for Transplantation Outcome in Patients Undergoing Reduced-Intensity Stem Cell Transplantation for Myeloid Malignancies , 2008, Acta Haematologica.

[57]  P. Armand,et al.  Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. , 2007, Blood.

[58]  F. M. Stewart,et al.  Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. , 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[59]  J. Voglová.  [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia]. , 2006, Vnitrni lekarstvi.

[60]  A. Elmaagacli,et al.  Outcome of allogeneic stem cell transplantation in patients with myelofibrosis , 2004, Bone Marrow Transplantation.

[61]  W Hasegawa,et al.  Stem cell transplantation for myelofibrosis: a report from two Canadian centers , 2003, Bone Marrow Transplantation.

[62]  H. Deeg,et al.  Splenectomy and hemopoietic stem cell transplantation for myelofibrosis. , 2001, Blood.

[63]  Russell,et al.  Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a ‘graft vs. myelofibrosis’ effect , 2000, British journal of haematology.

[64]  H. Deeg,et al.  Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. , 1999, Blood.

[65]  P. Morel,et al.  Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. , 1996, Blood.

[66]  C. Webb,et al.  The Delphi technique: a methodological discussion. , 1994, Journal of advanced nursing.

[67]  S. Brunet,et al.  Reduced transfusion requirements in a splenectomized patient undergoing bone marrow transplantation. , 1994, Acta haematologica.

[68]  S. Lewis,et al.  ALLOGENEIC BONE MARROW TRANSPLANTATION FOR PRIMARY MYELOFIBROSIS , 1989, British journal of haematology.